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Abstract
A meeting to discuss the latest developments in the biology of sexual development of Plasmodium and transmission-
control was held April 5-6, 2011, in Bethesda, MD. The meeting was sponsored by the Bill & Melinda Gates Foundation
and the National Institutes of Health, National Institute of Allergy and Infectious Diseases (NIH/NIAID) in response to the
challenge issued at the Malaria Forum in October 2007 that the malaria community should re-engage with the
objective of global eradication. The consequent rebalancing of research priorities has brought to the forefront of the
research agenda the essential need to reduce parasite transmission. A key component of any transmission reduction
strategy must be methods to attack the parasite as it passes from man to the mosquito (and vice versa). Such methods
must be rationally based on a secure understanding of transmission from the molecular-, cellular-, population- to the
evolutionary-levels. The meeting represented a first attempt to draw together scientists with expertise in these multiple
layers of understanding to discuss the scientific foundations and resources that will be required to provide secure
progress toward the design and successful implementation of effective interventions.
Background
It is now recognized that understanding and attacking
the parasites responsible for infection of the mosquitoes
is critical to the international efforts striving to eliminate
malaria [1]. Further, filling the gaps in the understanding
of parasite sexual biology could greatly help the develop-
ment of effective malaria transmission-blocking interven-
tions such as, but not limited to, vaccines and drugs. In
his introduction to the meeting Richard Carter said that
since the 2007 call to eradicate malaria, the field has
become both energized and focused to a degree not seen
in 50 years, concluding that malaria transmission reduc-
tion is once again a priority on the research agenda.
The objectives of the meeting were to:
￿ Develop a comprehensive landscape of research
initiatives, programmes, and funding vehicles in Plasmo-
dium gametocyte biology,
￿ Identify and prioritize key gaps in the knowledge
base and research agenda (see summary table of key
deliverables Table 1).
￿ Share and understand priorities of different institu-
tions working in this research area.
In convening this meeting, the NIH/NIAID and the
Bill and Melinda Gates Foundation (BMGF) created an
opportunity for international researchers and stake-
holders to share research updates, identify critical
experiments, and discuss the resources required to
advance these objectives. The key research questions
addressed by separate sessions of the meeting included:
1. What are the critical factors comprising/regulating
gametocyte biology?
2. What are the critical factors influencing transmis-
sion dynamics?
3. What are the best ways to target current and future
interventions?
4. What are the critical needs for the field to advance?
What are the critical factors comprising/
regulating gametocyte biology?
In recognizing the meeting would discuss sexual devel-
opment of all species of Plasmodium, it was highlighted
that in a minority of parasite species (in the subgenus
Laverania)e . g .Plasmodium falciparum sexual develop-
ment differs substantially from the majority (in the
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dium malariae, Plasmodium ovale, Plasmodium know-
lesi and Plasmodium berghei.T h ei m p o r t a n c eo f
recognizng the underlying molecular differences in
developmental strategies between these species-groups is
critical both to experimental analysis, and to the rational
design and understanding of interventions in the clini-
cal/field setting. For example, the protracted (9-12 day)
developmental period of gametocytes in P. falciparum
whilst offering a near unique opportunity to dissect
gametocyte maturation at the molecular level, results in
a totally different relationship between morbidity (and
therefore presentation to the clinic) and transmission, i.
e. while cases of vivax may be more infectious to mos-
quitoes prior to presentation at a clinic, falciparum
cases are more infectious after presentation.
Table 1 Summary of Key deliverables
Key deliverables to understand
transmission dynamics
￿ Understanding of the low levels of natural transmission
￿ Clarification of the relationships between the different methods of measuring transmission to the
mosquito
￿ Better definition of the infectious reservoir, and its role in control programmes
￿ Biomarkers to distinguish infectious from non-infectious hosts
￿ Improved integration of laboratory and field experimentation and data
Key deliverables to understand
gametocyte biology
￿ New markers for commitment to gametocytogenesis
￿ Improved methods for the purification of the different stages of sexual and sporogonic
development.
￿ Understanding of the pathways regulating sexual development (both gametocytogenesis and
gametogenesis)
￿ Understanding of parasite metabolism during sexual and sporogonic development
￿ Improved understanding of the molecular basis of fertilization
￿ Understanding of the mechanisms controlling gametocyte distribution in the host bloodstream.
Key deliverables for translation i) Vaccines
￿ Understand the biological relevance of membrane feeding assays
￿ Confirm structural and immunological fidelity of both current and new candidates
￿ New platforms to enhance and prolong antibody responses
￿ Designs for new field studies in a variety of endemic settings to evaluate TBVs alone and in
combination
￿ Develop bifunctional vaccines to attack both population bottlenecks (e.g. ookinete and liver schizont)
ii) Drugs
￿ Phenotypic screens for novel entities against gametocytes and ookinetes
￿ New target-based screens
￿ Understanding of the mode of action of primaquine
￿ Identification of dual activity compounds from the known library of 25,000 compounds with
schizonticidal activity
￿ Identification of novel transmission-blocking-specific compounds, to explore possible combinations
with blood schizonticides
￿ Methods for sustained drug delivery
iii) ‘Out-of-the-box’
￿ Reagents to modulate the mosquito innate immune system
￿ Understanding of the roles of natural-, or genetically modified- microflora in regulating malaria
transmission in the mosquito.
Key research tools required ￿ Molecular markers for all stages of sexual development
￿ Widespread availability of reagents for all ‘genes’ (GM parasites expressing tagged proteins or
knockouts; monoclonal antibodies)
￿ Improved access to high resolution, live imaging.
￿ Publicly available archives of numerical and microscopic data
￿ Wider access to transmission facilities
￿ GM rodent parasites expressing key proteins/gene-products from human malaria parasites
￿ Improved mathematical models of malaria transmission.
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Pietro Alano discussed commitment to, and differentia-
tion of, sexual stages at a cellular level. Pfs16 and Pfg27/
25-the first molecular markers of gametocytes of the
human malaria parasite P. falciparum, are expressed 24
hours into their development, Christian Doerig added
that Pfnek-4 expression might also identify sexually
committed gametocytes. It has been shown that all the
progeny from a single blood stage schizont are already
committed to become asexual parasites or either male
or female gametocytes [2,3]. Until recently the commu-
nity lacked markers to identify within a schizont which
path its progeny will take, however Kim Williamson
described a recent microarray analysis of P. falciparum
which identified 11 genes up-regulated in committed
parasites, three of which could be identified in ‘asexual’
schizonts. Christian Doerig noted that the normal excess
of schizonts that are not committed to gametocytogen-
esis makes studying the biochemistry of the committed-
few very challenging. Pietro Alano noted that recently
has it been possible to purify to virtual homogeneity
Stage-Ia gametocytes, thereby enabling differential pro-
teomics [4].
Following these presentations Chris Drakeley com-
mented that, while there is laboratory work indicating
that ‘stress’ induces gametocytogenesis, as posited by the
early studies of Sinton [5], in natural infections there
seems to be a constitutive commitment to sexual devel-
opment which itself may be modulated by extraneous
factors. Factors reportedly influencing gametocyte devel-
opment included host RBC age, hypoxia and exposure
to schizonticidal drugs. Notwithstanding the comment
that recent work in vitro stems from just one or two
strains of laboratory-adapted parasites, data presented
by Kim Williamson suggested in vitro gametocyte con-
version of P. falciparum is consistent with a constitutive
10% rate of induction. She too recognized that conver-
sion rates are more complex in the field, where parasi-
taemia alone does not predict gametocyte production,
and as suggested by the early studies, she surmised the
onset of clinical symptoms, if they occur, is a better
predictor.
Sarah Reece offered an evolutionary ecology perspec-
tive on malaria gametocytogenesis emphasizing the need
for its better analysis in order to understand malaria
transmission. For example, s h es u g g e s t e dt h ec o n v e n -
tional view that malaria transmission will cease when
basic reproductive rate (Ro) is reduced to less than one
(see below) may not hold. Under transmission reducing
measures, theory suggests parasites may adjust their
gametocyte sex ratio to maximize their reproduction
and thereby raise Ro again [6]. Because sex allocation
rules fit very diverse taxa [6], there is hope that knowl-
edge on sex allocation obtained from the study of
rodent malarias in the laboratory will be relevant to
human malaria transmission.
How do gametocytes develop and differentiate
and get ready for the flight?
Pietro Alano reported that kinase knockouts (KO’s) do
not affect gametocyte production. Compared with mero-
zoites, he noted that young gametocytes have a very
high level of expression of export-related proteins [7],
that erythrocytes containing young gametocytes have a
very low antigenic profile, and knobs- structures that
are associated with sequestration of asexual blood stages
(ABS), are not displayed on the surfaces of the gameto-
cyte-infected red blood cell (giRBC). Immature gameto-
cytes of P. falciparum do nevertheless sequester and
there is a need to identify the parasite molecules
involved.
Bob Sinden discussed the cellular organization of
mature gametocytes. Mature gametocytes of both sexes
while sensitive to inhibitors of respiration, are less sensi-
tive to anti-metabolites and schizonticides than the
immature forms and asexual stage parasites [8-10].
Mature male and female gametocytes differ markedly at
both the molecular and cellular levels. The female is a
typical eukaryotic egg cell having a well-developed endo-
plasmic reticulum, mitochondrion and apicoplast in pre-
paration for rapid development as a zygote. This rapid
development is mediated in part by DOZI-regulated [11]
translationally repressed mRNA species, encoding ‘early
translated proteins’ such as P28, these messengers are
located in discrete foci in the cytoplasm [12]. The
mature male gametocyte, by contrast, has a markedly
reduced ribosome and endoplasmic reticulum network;
it will contribute only plasma membrane, nucleus and
an axoneme to the male gametes and zygotes. Osmio-
philic bodies are found in both male and female game-
tocytes but are more abundant in the latter; these
secretory organelles are involved in the parasites’ escape
from the red blood cell (RBC) during gametogenesis
[13,14].
Kim Williamson further discussed the biochemistry
and gene expression of gametocytes. As indicated above,
protein synthesis and degradation are essential for
gametocyte maturation. The Alamar Blue viability stain
confirms that gametocytes are metabolically active and
can be targeted with antimetabolites e.g. epoxomicin
and cycloheximide [15]. Work is in progress on assays
to identify essential metabolic pathways in gametocyte
maturation; it has been shown that pyrimidine biosynth-
esis is not required. It was suggested a more profound
understanding of the variations in metabolism between
the different sexual stages (immature/mature; male/
female; gametocyte/gamete) is needed to provide a
secure appreciation of the observed inability of the
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mission stages.
What happens during gametogenesis?
Oliver Billker inferred gametogenesis is optimized for
speed not quality of outcome. From the moment of
their induction to undergo gametogenesis, gametocytes
of both sexes take around ten minutes to complete
“rounding up” and emergence from the RBC, simulta-
neously the male undergoes “exflagellation” to release
the 8 male gametes. Induction is triggered by a drop in
temperature, an increase in intracellular pH, and expo-
sure to the mosquito exflagellation factor xanthurenic
acid (XA) in the mosquito blood meal [16]. Within the
gametocytes, kinases are involved in the regulatory acti-
vation pathways [17]. Reverse genetics has been particu-
larly helpful to dissect regulatory pathways in
gametocytes - there are good phenotypes and phenoty-
pic assays - but improvements in this area are needed.
There is a project at the Sanger Institute, UK, to scale
up reverse genetic approaches to provide a large library
of gene-targeting vectors for P. berghei.Q u e s t i o n st h a t
remain unanswered include: “What is the origin of XA
in the blood meal?”,a n d“Can one activate gametocytes
in the blood stream to eliminate their transmission
potential?”
Nirbhay Kumar discussed cellular events and molecules
in gametogenesis. To achieve this inside a mosquito blood
meal, the parasite must adapt to a new pH-, temperature-,
ionic/nutritional- environments, and to the components of
the vertebrate and mosquito hosts immune systems to
which the parasites are exposed. Potassium (K+) channels
could play a role as possible drug targets. Knockout of the
encoding gene (pfkch1) leads to loss of gametocyte infec-
tivity in the mosquito [18].
Gene expression and gene control in gametogenesis
was addressed by David Baker. Little is known in this
area, beyond the key role of translation control mechan-
isms. The radically different environments of the host
blood circulation, where the mature gametocytes exist
in a quiescent state and that in the mosquito blood
meal, present opportunities for the parasite to switch
the pattern of gene expression. But to what extent does
this take place? Do the environmental cues connect with
signalling pathways leading to changes in gene expres-
sion? He reported that initial microarray analysis sug-
gests there is a global regulation of both stage-specific
transcription [19], and of steady state RNA levels.
What happens during fertilization and after?
Andy Waters discussed the rapidly-completed cellular
and molecular events of fertilization, which occur in the
hostile environment of the blood meal. Male microga-
mete motility is fuelled by glycolysis, which is druggable
[20]. In fertilization, a family of proteins posessing 6-
Cysteine (6-Cys) domains (P45/48, P47, and P230) are
expressed on the surfaces of gametes of both sexes;
there is evidence that they are involved in fertility. 6-Cys
KO’s result in the production of very few ookinetes in
vitro, and cause a 20-50 fold reduction in the parasites’
transmissibility to mosquitoes. The female gametocyte
transcriptome is overwhelmingly silenced in the RNA
helicase-DOZI (Development Of Zygote Inhibited) KO
[11], but protein translation is rapidly resumed during
gametogenesis. In recognizing the common basis for
motility of the merozoites, sporozoites and ookinetes, he
suggested ookinete motility could be a target for multi-
stage drug development.
Dietlind Gerloff described structural modelling of the
gamete surface protein P230, an in silico activity [21,22]
that has complemented the crystallographic studies on
the ookinete surface protein P25 [23]. In 2005, the first
three dimensional structure was produced for P230, sug-
gesting its structural similarity to the Toxoplasma gondii
surface protein SAG1 [21]. The domain structure of
P230 is specific to apicomplexan parasites; the size of a
single domain in this protein and its 6-Cys relatives was
similar to that of the immunoglobulin fold. It was sug-
gested the value of the structural models is that they
can guide further experiments with these molecules and
refine understanding of their interactions.
The genetics of fertilization and of the interactions of
malaria parasites with mosquitoes was addressed by Lisa
Randford-Cartwright. Both male and female gametocytes
can be generated from a single haploid clone, sex is not,
therefore, determined by sex specific chromosomes.
Gametes of the same clone both self-fertilize (forming
homozygotes) or cross-fertilize (forming heterozygotes)
with equal frequency. Mating appears to be random
between gametes of different genotypes [24,25] the
resulting zygote is briefly diploid before the nucleus
undergoes meiosis [26]. From laboratory crossing experi-
ments, there is no evidence for mating types within gen-
der, i.e. preferential mating, or exclusion of mating,
between parasites of specific genotypes. When investigat-
ing natural malaria transmission people are generally
found to be infected with at least two genetically distinct
clones of malaria parasite of a given species. In wild-
caught mosquitoes both homozygous and heterozygous
oocysts have been observed [27] confirming that both
selfing and crossing happen in the field. In laboratory
experiments, vector efficiency is frequently higher with
co-indigenous strains of Plasmodium and mosquito [28].
Linkage/quantitative trait locus (QTL) analysis is cur-
rently being employed to look at the genetic basis of such
parasite strain/vector species specificity.
Bill Snell discussed fertilization in protists. The free-
living protist, Chlamydomonas,a p p e a r st ob eau s e f u l
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easy to manipulate, has well-characterized biology, and
can be manipulated by the introduction of transgenes,
but current evidence suggests this rarely occurs by
homologous recombination [29]. Hap2 was discovered
to be important for membrane fusion during fertilization
in both Chlamydomonas and Plasmodium [30]. Hap2 is
as i n g l ep a s st r a n s m e m b r a n eprotein that is absent in
vertebrates but is widely conserved in plants, bees, Try-
panosoma, Toxoplasma,a n dEimeria.T h ef u s i o n
mechanism is likely to be conserved across these groups
of organisms; on the other hand the initial coupling of
cells is expected to be achieved by species-specific
proteins.
What are the critical factors influencing
transmission dynamics?
The main objective of this session was to describe what
is known about the dynamics of natural infectivity and
the human reservoir of infection, and subsequently to
identify some of the knowledge gaps related to the fun-
damental basic biology of gametocytes. It was recog-
nized that malaria transmission is focal, i.e. it occurs
within spatially limited areas - each focus of transmis-
sion is determined by the locations of vector mosquito
breeding sites and the flight patterns of the resident
anopheline vectors responsible for parasite dissemina-
tion. As defined by the Ross/MacDonald equation,
malaria transmission is dependent upon many different,
and targetable, biological events, which must be consid-
ered in concert and not in isolation. If the malaria case
multiplication rate, Ro, is greater than 1, malaria trans-
mission will be sustained within each focus. If Ro con-
sistently falls below 1, the focus will cease to sustain
transmission. As a very rough approximation, it was
hypothesized any single intervention may be expected to
reduce Ro by two- to four-fold when randomly applied
(Saul, A, pers comm.; Carter R, unpublished). It was
suggested targeting multiple interventions to sites of
high transmission may increase their impact by a further
two- to four-fold. By combining different interventions,
powerful overall reductions in malaria transmission may
be achieved if, and when, the reductions due to the indi-
vidual interventions multiply together. Within a focus of
transmission, malaria case incidence rates vary markedly
across distances as short as a few tens of meters, and
between foci malaria transmission rates can vary by
orders of magnitude across distances of a few hundred
metres to kilometres [31-33], distances that lie well
within the flight distance of the mosquito. Because of
this spatial heterogeneity in transmission even within a
‘focus’, transmission-blocking measures are predicted to
be most effective when targeted to the specific locations
of highest transmission intensity [31,34].
Recent descriptions of the basic biology of P. falci-
parum have, of necessity, relied on data generated from
a limited number of laboratory strains in highly con-
trolled experimental conditions. Data from the first half
of the 20
th century [35] suggest the kinetics of gameto-
cyte production, carriage and infectivity in diverse hosts
living in areas of different malaria endemicity is likely to
be much more complex than observed in vitro. Under-
standing some these complexities may lead to the dis-
covery of new subtle and species-specific adaptations
that facilitate transmission. Chris Drakeley provided an
overview of the current epidemiological data related to
P. falciparum gametocyte carriage and infectivity. He
suggested one of the most important recent field obser-
v a t i o n si st h ec o n f i r m a t i o no fp r i o r‘malaria-therapy’
data [36] that high/sustained levels of gametocyte car-
riage can be frequently observed. These new field obser-
vations are based on sensitive molecular amplification
techniques and show that in several in vivo anti-malarial
treatment studies the prevalence of gametocytes on
enrolment is in the order of 80-90% compared with the
15-30% measured by microscopy [37]. This might sug-
gest that gametocytogenesis occurs much earlier in the
infection than commonly thought and that the classic
‘stress’ phenomena perceived to be essential for in vitro
gametocytogenesis (see above) may be different to those
acting in vivo. Importantly these sub -patent/micro-
scopic gametocyte densities are infectious to mosquitoes
[38]. They invariably result in low prevalence and inten-
sity of mosquito infection, but this may be ‘offset’ by the
host being infectious for longer than previously
assumed, for example in chronic infections in semi-
immune adults.
Recognizing the numerous extraneous factors that reg-
ulate the infectivity of mature gametocytes [39], the rela-
tionship between gametocyte density and infectivity is
unpredictable, especially in the case of P. vivax in SE
Asia where a higher proportion of patients are infectious
compared to P. falciparum (Jetsummon Sattabongkot).
Similar data were observed in South America (Jo Vinetz)
with a variety of parasite and host factors incriminated,
including immune and metabolic mediators, of these the
impact of sexual schizogony on P. vivax gametocyte
infectivity has been particularly well-documented [40].
The role of the relative susceptibility of in- and out-bred
vectors as modulators of transmission was also raised as
an additional yet unknown variable.
The session continued with detailed presentations on
the interactions between gametocytes and their human
hosts (Teun Bousema). Little is known about the ligands
that mediate interactions between the gametocyte-
infected RBC (giRBC) and the human host, though
there are several candidates such as the STEVOR and
the RIFIN families of exported proteins. Gambian
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late stage gametocyte-infected erythrocytes independent
of asexual parasitaemia and these responses correlated
with reduced gametocyte carriage (Colin Sutherland).
The field currently lacks both assays to evaluate P. falci-
parum gametocyte sequestration, and specific reagents
to investigate these phenomena. The identification of
biomarkers to identify persons harbouring infectious
gametocytes was considered paramount. Using data
obtained from a flow-based technique to examine the
deformability of gametocytes at different stages of devel-
opment, Pierre Buffet and Catharine Lavazec described
interactions between the giRBC and the spleen - a site
implicated in gametocyte sequestration.
It was noted that little has been done to look at the
co-evolution of human and parasite genetics in relation
to infectivity to the vector. It was muted that the human
genotypes influencing the development of asexual para-
sites may directly or indirectly modulate transmission
(David Modiano), examples of such interactions have
been documented previously [39].
The practical implications of targeting gametocytes
and infectious individuals in intervention campaigns
were presented. Lucy Okell proposed that mass drug
administration will have most success in reducing trans-
mission. The practicality of targeted approaches depends
on the sensitivity of the diagnostic to identify parasite
carriers. Recognizing that a majority of infected persons
are gametocyte carriers, it was asked whether simple,
more robust and sensitive methods to detect asexual
parasites might provide a more cost effective approach
to the identification of potentially infectious individuals.
Geoff. Targett and Gillian Stresman highlighted that
many of the problems in targeting interventions to the
appropriate population are shared with other control
approaches, notably how one identifies the individuals
to be targeted in both short-term and stable foci, in hot-
spots within these foci, and in travellers? In the absence
of a transmission-blocking vaccine (TBV), current active
transmission reduction approaches rely on drugs. There
remain issues as to the best anti-malarials to use, prima-
quine currently being the only available gametocytocidal
compound. The effect of artemisinin combination ther-
apy (ACT) on transmission may be over-estimated
because despite reducing gametocyte carriage [41] the
few gametocytes that remain after treatment, as found
with chloroquine treatment [42], can be very infectious
(Abdoulaye Djimde).
What are the best ways to target current and
future interventions?
Recognizing the focus of the malaria eradication agenda
has now expanded from the previous focussed objective
of reducing morbidity and mortality in the human host,
to protection against neo-infections, it is necessary to
e m b r a c et h ek e yt a r g e to ft r a n s m i s s i o nr e d u c t i o n .A n
expanded array of interventions must therefore be envi-
saged. These may include measures to either inactivate
or eliminate parasites in both the human host and the
mosquito vector, with for example drugs, vaccines, biolo-
gical control (fungal or bacterial pathogens of mosqui-
toes) or genetic strategies to reduce mosquito
populations or their susceptibility to Plasmodium.
Patrick Duffy reviewed the current interest in TBV.
Rational development of TBVs requires that putative
target proteins, on the surface of extracellular parasites
in the mosquito vector, or components of obligate path-
ways and interactions, are better characterized by
‘omics’ approaches. To date, 24 proteins have been
described as being inducers of potential transmission-
blocking antibodies. Of the current lead candidates, two
are expressed on the surface of gametes and in the
intracellular compartment of gametocytes (P48/45 and
P230), two others, P25 and P28 on the surface of the
ookinetes. While producing protein antigens of appro-
priate immunogenicity remains challenging, it was sug-
gested that solutions do exist e.g. Pseudomonas
aeruginosa exo-protein A (EPA) [43] and Corynebacter-
ium diphteriae cross-reactive material 197 (CRM197)
[44] have been proven effective delivery mechanisms.
The question of deciding on the right target product
profile for a TBV needs to be revisited carefully and
should include integration of vaccines with other inter-
ventions. Identifying the target population for a (long-
lived) TBV may be more straightforward than for a
(short-lived) drug, Dr Duffy suggested every infected
individual should be considered to be capable of trans-
mitting the disease and therefore everyone in the area of
transmission should be immunized with a TBV. This is
in marked contrast to existing vaccine delivery systems
in malaria endemic regions which target infants. There
is now a trend toward performing Phase-1 trials in
endemic settings. Considering that malaria transmission
is focal, understanding micro-epidemiological transmis-
sion patterns in such settingsi sa ne s s e n t i a lp r e - r e q u i -
site to the determination of which geographic foci
within the community should be preferentially targeted.
Didier Leroy reviewed the agenda for discovery of
transmission-blocking drugs (TBD). The identification
and validation of new potential drug targets are two
highly challenging and time consuming processes what-
ever disease is considered. To date, screening of asexual
blood stages of P. falciparum has been much more suc-
cessful than molecular target-based approaches and has
generated up to 25,000 hits with potencies below 1.5
μM. This is now being complemented effectively with
work on a limited number of genetically validated mole-
cular targets with essential roles in parasite development
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tially play key roles in the formation of gametes and
ookinetes respectively. Similarly PfPK7 - essential for
oocyst maturation in the mosquito midgut, might be
targeted by long-lasting drugs, these might prove to be
challenging to develop (see below). Despite the arsenal
of new generation high tech assays and readouts, no
medium/high throughput solution is currently available
to screen sporonticidal compounds. It is urgent that the
generation of ‘omics’ data is completed to improve
understanding of the molecular regulation of sexual
development, e.g. in late gametocytes, the digestion of
haemoglobin is turned off, and ‘simultaneously’ mito-
chondrial function and the tricarboxylic acid (TCA)
cycle are turned on.
In attempting to reduce Ro, gametocytes, and particu-
larly their mature forms (stage V), may prove to be key
targets for transmission-blocking agents. Clinical studies
have shown primaquine efficiently eliminates gameto-
cytes [45], notably when combined with sulphadoxine-
pyrimethamine and artesunate [46]; the pathways, meta-
bolites and molecular targets of primaquine remain to
be identified. It can reasonably be hypothesized that elu-
cidating the mode of action of primaquine against
gametocytes would pave the way for the discovery of
new anti-malarials.
Today, better assays are needed to investigate the
downstream impact that drugs, administered to the
gametocyte in the human host, might have on develop-
ment within the mosquito vector and transmission.
From a drug development perspective such drugs are
attractive because of the comparative simplicity of drug
delivery. By contrast the design of drugs specifically tar-
geting the ookinete requires that the compound has a
half life that matches that of the mature gametocytes.
While this is readily achieved in the majority of malaria
species (where gametocytes have a very short 1-2 day
half life), it is more difficult with P. falciparum (where
mature gametocytes can survive for up to three weeks).
Targeting the oocyst with drugs (or vaccines) is even
more problematic, because the deliverability and expo-
sure of oocysts to drugs is impossible to control, poten-
tially leading to the risk of accelerated selection of
resistance.
Considering the current level of knowledge of anti-
malarials targeting the asexual parasites in human blood
and the constraints of drug development, one ongoing
strategy to identify transmission-blocking drugs is to
screen known blood schizonticides against late stage
gametocytes. Today, the possibility of pursuing a drug
development programme on a molecule that would
block transmission but wouldn’t cure the disease in the
t r e a t e dh o s ti sa l s or e c o g n i z e da sav a l i da n dv a l u a b l e
addition to our armamentarium. This will necessitate
unbiased screening of large compound libraries against
gametocytes and ookinetes. A novel concept of using
drugs to induce gametogenesis in the human host was
suggested. This has a two-fold attraction: first, the trea-
ted parasite will be incapable of transmission and sec-
ond, the formation of gametes in the human host would
require the expression of known potent transmission-
blocking (neo) antigens (such as P25, P28) thus enhan-
cing the impact of natural transmission-blocking immu-
nity. Recognizing that, naturally, > 99% of gametocytes
will die within the human host and thus present anti-
gens to the immune system, it was appreciated that
responses to gametocyte antigens per se (e.g. P230, P48/
45) would not be significantly enhanced.
Carolina Barillas-Mury reviewed interventions target-
ing the parasite in the vector; she emphasized past wis-
dom that the only malaria control strategies that have
been successful to date have included a component that
controls the vector. The mosquito’si m m u n es y s t e m
lacks an adaptive immune response arm and, therefore,
no malaria-specific immune response awaits a subse-
quent infection. Recognizing the innate immune
response is the only protection the mosquito can rely
on to fight against the parasite, an interesting feature is
the ability of the IMPer/Duox pathway to regulate the
response when the midgut is invaded by parasites or
bacteria. When this system is silenced/inhibited, the
mosquito’s midgut immune system efficiently reduces
oocyst numbers. This interesting regulatory pathway
needs to be further investigated and the possibility to
inactivate this system specifically in mosquitoes, either
directly with insecticides or indirectly with a partner
drug in a combination therapy, has to be assessed. It
would be interesting to know whether other similar
pathways might be open to attack.
What are the critical needs for the field to
advance?
The following synopsis divides the conclusions reached
into two distinct areas: firstly outstanding questions
concerning the biology of the sexual stages of malarial
parasites that are considered to be too fascinating and
fundamentally important to our understanding of life
processes to be overlooked, irrespective of whether they
may have potential application; and secondly those areas
where it is essential to develop a greater understanding
to discover, develop and apply effectively interventions
targeted to the sexual stages. It was clear to many parti-
cipants that all too obvious opportunities for potent
interventions against transmission of Plasmodium to the
vector have been neglected for ~40 yrs. It might be
anticipated that the substantial body of available knowl-
edge accrued in this period of neglect might rapidly be
converted into new and effective interventions.
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Induction of sexual development
The basic questions as to how the developmental deci-
sion between asexual and sexual development is induced
and regulated remain at the forefront of the key
unknowns. Fundamental issues as to whether the switch
is constitutive and/or subject to qualitative or quantita-
tive ‘environmental regulation’ remain unresolved and
contested. Investigators must be prepared to ask
whether this regulation differs between the parasite spe-
cies. Whilst it is clear that in some species merozoites
released from the pre-erythrocytic schizont can be com-
mitted to the sexual pathway (as it is in many ‘primitive’
haemoproteids) [47], it remains unclear as to whether,
following RBC infection, there may be specific environ-
ments in the vertebrate host where induction is more
common. Recent Piggy-Bac mutagenic studies on P. fal-
ciparum have identified for the first time genes essential
for gametogenesis that are detected in cells that mor-
phologically cannot be identified as gametocytes; this
could be key to the identification of a switch described
in the preceding sexually committed asexual schizont.
The genetic regulation and molecular mechanisms of
sexual differentiation
Although this field is developing rapidly the molecular
basis underpinning the morphological, metabolic and
functional maturation of gametocytes is poorly under-
stood. The potential power of systematic ‘omics’ tech-
nologies remains compromised by the large number
~50% of the malarial genes that remain un-annotated.
Data generated to date have provided a rational explana-
tion for the induction and specificity of natural immu-
nity to gametocyte antigens. The fascination of
understanding the genetic and ‘environmental’ control
of sexual development; the roles of genetic master-regu-
lators’ e.g. AP2, and DOZI; the roles of individual genes;
of the design, assembly and functions of molecular
machines and organelles was apparent to all. Nowhere is
this curiosity more challenged than in the ‘explosive’
process of male gamete formation, where rates/mechan-
isms of DNA replication and axoneme assembly chal-
lenge any current understanding. From, and for, such
studies improved markers of the numerous stages of
sexual development must emerge.
Probably the biggest gap in the understanding of
gametocyte maturation is the molecular description of
gametocyte metabolism. Inhibitor/drug studies suggest
significant differences between the immature (tropho-
zoite-like) and morphologically mature (arrested in Go)
gametocytes (protein synthesis being down-regulated in
the latter). Mitochondrial/energy production pathways
throughout sexual development and early sporogonic
development may provide a rich vein to be mined. Such
studies will benefit from standardized culture methodol-
ogies, and would provide one route to the development
of effective drugs to block transmission.
The biology of sexual development in the infected host
and mosquito vector
There was considerable debate as to the molecular basis
for the sequestration of immature P. falciparum gameto-
cytes, and the need for appropriate markers/tools to
study the phenomenon, the relevance of this topic, if
any, to any parasite species outside the subgenus Laver-
ania whilst unclear, was not discussed.
Clearly despite significant recent advances, the mole-
cular basis of gamete-gamete recognition, gamete fusion
and onward zygote development remains poorly under-
stood. The parallel influences of immunological drivers
of polymorphism in gamete surface proteins and the
evolution of species-specific mechanisms of fertilization/
zygote survival proffer fertile ground for theorists.
Whilst recognizing the ‘dominant’ role of the large
female gamete it is appropriate to ask what roles the
incredibly simple male gamete plays in development e.g.
determination of the polarity and subcellular coordina-
tion of the assembly and functions of the zygote/
ookinete.
The complexity of malaria transmission through ende-
mic populations was evident, key issues raised (but not
fully understood) include differential transmissibility of
parasite species, mixed species infections and genotypes;
differential susceptibility of vector species and geno-
types; the impact of human genotype; focality of trans-
mission and intensity of transmission. Not least amongst
the theoretical and practical questions raised was how
these variables contribute to the definition of the reser-
voir of infection.
Translation from knowledge to intervention
The necessity of understanding the impact of spatial and
temporal distributions of infectious persons in modelling
malaria transmission, and tailoring the design of inter-
vention campaigns to areas of differing endemicity is
clear, but recognizing the high prevalence of gametocyte
carriage in infected persons the meeting was asked
whether, during the implementation of an intervention
campaign it is necessary to distinguish infectious from
infected persons? The method by which infections are
detected (active vs. passive case detection) remains criti-
cal, because the contribution of asymptomatic persons
to the infectious reservoirs needs to be understood for
an appropriate plan of intervention to be designed in
each locality. If the operational model in the field
remains either mass drug administration (MDA), or the
detection and treatment of all malaria-infected indivi-
duals, every infected person will merit treatment to
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transmission-blocking compounds with schizonticidal
drugs obviously addresses this need, and has been
shown to be a most effective intervention strategy [48].
The potential of vaccines with transmission-blocking
potential undoubtedly has a key role to play in any elim-
ination/eradication agenda, whether in the treatment of
focal areas of transmission or more broadly. All else
being equal (immunogenicity; antigen diversity; longevity
of effective response etc.) the theoretical advantage of a
vaccine that might be boosted by any subsequent infec-
tion is clear, but still requires experimental validation. It
was recognized that there would be significant advan-
tage if the delivery of a transmission-blocking drug
could be engineered to emulate that of a vaccine (pro-
longed delivery from a depot). It was also recognized
that despite notable individual successes the discovery
and development of both transmission-blocking vaccine
and drug targets have to-date lacked rational genome-
based discovery and prioritization.
A review of current progress in TBV development
(Ashley Birkett) emphasized the current TPP is for a
protein vaccine with a non-controversial adjuvant,
which, if administered in no more than three doses
within a six-month period would result in 85% blockade
of mosquito infection intensity. Current focus is on
Pfs48/45; Pfs25 and the mosquito antigen APN1. Recog-
nizing that other candidates are under active investiga-
tion [49,50] it would be reassuring if it could be shown
unequivocally that these are the best possible candidates.
It was recognized that future needs must include
research into vaccines targeted to P. vivax, and agree-
ment on the development pathway, including standar-
dized/harmonized assays of vaccine efficacy.
The objectives of development of new anti-malarials
has been broadened, schizonticide discovery/develop-
ment has been complemented by the clear recognition
of the need to inhibit malaria transmission. Whilst
acknowledging that early delivery of effective schizonti-
cides will have a significant impact upon gametocyte
production, and therefore transmission, two biological
transmission targets have been prioritized: the hypno-
zoite (P. vivax; P. ovale); and sexual development (all
species), for which the TPP is for fast-acting, long-lived
drugs. It is recognized that the very small number of
parasites at these critical phases of development theore-
tically offers the promise of slow selection of resistance,
a problem that has blighted the development of the cur-
rent generation of schizonticides. Such drugs might use-
fully complement diverse intervention strategies.
’Out-of-the-box’ (i.e. non-drug, non-vaccine) thinking
reminded the attendees of the now-proven potential of
GM vectors, and para-transgenic approaches using mos-
quito symbionts/pathogens to express anti-parasitic
moieties. The group highlighted the recent observations
as to how the mosquito midgut microflora moderates
the innate immune response and malaria infections, and
raised interesting questions as to the indirect impact of
current/future interventions upon the balances within
this particular ecosystem. Significant thought will be
needed to determine how these methods might be
applied effectively in field situations.
Tools needed to respond to the challenges ahead
The molecular level
Many participants highlighted the need for powerful
markers of expression of all sexual-stage genes. The
value of expanded repositories of research tools e.g.
gene knockouts, tagged proteins, monoclonal antibodies
and the wider availability of high resolution in vivo ima-
ging technologies cannot be overemphasized. With these
improved tools it will be possible for community-wide
action to analyse the function/impact of sexual stage
genes, their chemical biology, and undertake HTP
immunological studies on parasite biology. All HTP
methods of parasite protein analysis remain critically
dependent upon improved genome annotations of all
relevant organisms, without this the recognized need for
the discovery of the best vaccine, drug and other targets
cannot be undertaken rationally or effectively.
The experimental level
The contrast between the experimental tractability of the
rodent malaria parasites (notably P. berghei) and the para-
sites of man was noted. In particular it was recognized
that some of the tools currently used to determine the
impact of transmission-blocking strategies on the human
parasites are slow, expensive and available to few groups,
e.g. Cat III culture facilities and secure insectaries. Even
more exclusive were facilities to work on primate hosts
with the consequence that abilities to study the transmis-
sion of P. vivax,o rP. knowlesi are rare, and of the remain-
ing species (P. ovale, P. malariae) or of mixed-species
infections almost non-existent. The challenge of develop-
ing new safe and widely useable (preferably at the HTP
level) analytic methods must be addressed. An area of
immediate need is the requirement to understand the cor-
relation between the various assays used to report the
impact of transmission-blocking vaccines.
One proven, albeit still low throughput, approach to
some of the problems above has been the production of
transgenic rodent malarial parasites in which the rele-
vant endogenous gene of interest has been replaced by
the homologue from the human parasite. Where such
exchanges are not complicated by fine molecular incom-
patibilities, these have a unique additional benefit in
that the organism may not infect man thus removing
major cost and security limitations to their study.
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Outstanding questions of transmission biology that con-
found the development of rational mathematical models
include first, the need to understand heterogeneities at
all levels of biology, from the gene through the biologies
of the interacting organisms, of inter-personal infec-
tiousness to the vector, to the spatial and environmental
variations in parasite distributions in endemic commu-
nities. A second requirement is the need to recognize
and define the recently recognized non-linearities in
parasite dynamics [51,52] as they pass through the
sequential phases of their life cycles, noting that these
relationships may be subject to significant species-speci-
fic variations in host, parasite or vector.
One outstanding question that impacts upon the
design of any effective transmission-blocking interven-
tion is how to design and conduct appropriate field
trials. Whilst this has been addressed in significant
depth by other meetings [53] it is clear that diverse
views remain. It might emerge that the design of trials
of (transmission-blocking) bed nets could act as a secure
framework for these deliberations.
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